Cargando…

Impact of Glucocorticoid Cumulative Doses in a Real-Life Cohort of Patients Affected by Giant Cell Arteritis

Objectives: To describe the impact of cumulative glucocorticoid (GC) doses on related adverse events (AEs) in giant cell arteritis (GCA) in a real-life setting. Methods: The medical charts of the last 139 consecutive GCA patients followed in a tertiary centre were retrospectively analysed. The cumul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castan, Paul, Dumont, Anael, Deshayes, Samuel, Boutemy, Jonathan, Martin Silva, Nicolas, Maigné, Gwénola, Nguyen, Alexandre, Gallou, Sophie, Sultan, Audrey, Aouba, Achille, de Boysson, Hubert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875204/ https://www.ncbi.nlm.nih.gov/pubmed/35207305 http://dx.doi.org/10.3390/jcm11041034

Ejemplares similares

Evolution of the Therapeutic Management of Giant Cell Arteritis: Analysis of Real-Life Practices over Two Timeframes (2014–2017 and 2018–2020)
por: de Boysson, Hubert, et al.
Publicado: (2023)

Impact of Giant Cell Arteritis and Its Treatment on the Patient's Quality of Life: A Single-Center Self-Assessment Study
por: de Boysson, Hubert, et al.
Publicado: (2021)

Giant-cell arteritis without cranial manifestations: Working diagnosis of a distinct disease pattern
por: de Boysson, Hubert, et al.
Publicado: (2016)

An Updated Review of Cardiovascular Events in Giant Cell Arteritis
por: de Boysson, Hubert, et al.
Publicado: (2022)

Whole‐Country and Regional Incidences of Giant Cell Arteritis in French Continental and Overseas Territories: A 7‐Year Nationwide Database Analysis
por: Guittet, Lydia, et al.
Publicado: (2022)

(18)F-fluorodeoxyglucose positron emission tomography and the risk of subsequent aortic complications in giant-cell arteritis: A multicenter cohort of 130 patients
por: de Boysson, Hubert, et al.
Publicado: (2016)

[(18)F]FDG PET-MR characterization of aortitis in the IL1rn(−/−) mouse model of giant-cell arteritis
por: Deshayes, Samuel, et al.
Publicado: (2023)

Sustained Response and Rationale of Programmed Cell Death-1-Targeting for Progressive Multifocal Leukoencephalopathy
por: Audemard-Verger, Alexandra, et al.
Publicado: (2019)

Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis
por: de Boysson, Hubert, et al.
Publicado: (2021)

Chronic intestinal pseudo-obstruction with dilated biliary tract as a spectrum of stiff person syndrome in a nondiabetic patient
por: Nguyen, Alexandre, et al.
Publicado: (2019)

Risk Associated with Cumulative Oral Glucocorticoid Use in Patients with Giant Cell Arteritis in Real-World Databases from the USA and UK
por: Gale, Sara, et al.
Publicado: (2018)

Anakinra for patients with COVID-19
por: Martin-Silva, Nicolas, et al.
Publicado: (2020)

Intra-Alveolar Haemorrhage Complicating IgA Vasculitis: A Case Report, Literature Review and Discussion of Treatment
por: Savoye, Benjamin, et al.
Publicado: (2019)

Presentation and Real-World Management of Giant Cell Arteritis (Artemis Study)
por: Mahr, Alfred, et al.
Publicado: (2021)

The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis
por: Jakobsson, Karin, et al.
Publicado: (2016)

Bone mineral density in patients diagnosed with giant cell arteritis taking glucocorticoids: a case–control study
por: Geressu, Adam, et al.
Publicado: (2023)

Stratified glucocorticoid monotherapy is safe and effective for most cases of giant cell arteritis
por: Karabayas, Maira, et al.
Publicado: (2020)

Prognostic impacts of glucocorticoid treatment in patients with polymyalgia rheumatica and giant cell arteritis
por: Emamifar, Amir, et al.
Publicado: (2021)

Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis
por: Tomelleri, Alessandro, et al.
Publicado: (2022)

Genetic Predispositions of Glucocorticoid Resistance and Therapeutic Outcomes in Polymyalgia Rheumatica and Giant Cell Arteritis
por: Smutny, Tomas, et al.
Publicado: (2019)

Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis
por: Best, Jennie H, et al.
Publicado: (2019)

Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering
por: Venerito, Vincenzo, et al.
Publicado: (2022)

Glucocorticoid Effects on Tissue Residing Immune Cells in Giant Cell Arteritis: Importance of GM-CSF
por: Wagner, Annette D., et al.
Publicado: (2021)

Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab
por: Stone, John H., et al.
Publicado: (2019)

Giant Cell Arteritis
por: Coulier, Bruno, et al.
Publicado: (2018)

Giant Cell Arteritis versus Takayasu Arteritis: An Update
por: Stamatis, Pavlos
Publicado: (2020)

A qualitative study of patient perspectives related to glucocorticoid therapy in polymyalgia rheumatica and giant cell arteritis
por: Hoon, Elizabeth, et al.
Publicado: (2019)

Rapid glucocorticoid tapering regimen in patients with giant cell arteritis: a single centre cohort study
por: Mensch, Noemi, et al.
Publicado: (2023)

Treatment of Giant Cell Arteritis and Takayasu Arteritis—Current and Future
por: Hellmich, B., et al.
Publicado: (2020)

Specific microbiome profile in Takayasu’s arteritis and giant cell arteritis
por: Desbois, Anne Claire, et al.
Publicado: (2021)

Recovery of Adrenal Function after Long-Term Glucocorticoid Therapy for Giant Cell Arteritis: A Cohort Study
por: Jamilloux, Yvan, et al.
Publicado: (2013)

From Active to Non-active Giant Cell Arteritis: Longitudinal Monitoring of Patients on Glucocorticoid Therapy in Combination With Leflunomide
por: Kuret, Tadeja, et al.
Publicado: (2022)

Influence of factor VIII level and its inhibitor titer on the therapeutic response to corticosteroids alone in the management of acquired hemophilia: A retrospective single-center study
por: Vautier, Mathieu, et al.
Publicado: (2016)

Correction: Recovery of Adrenal Function after Long-Term Glucocorticoid Therapy for Giant Cell Arteritis: A Cohort Study
por: Jamilloux, Yvan, et al.
Publicado: (2013)

Metabolic features and glucocorticoid-induced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohort
por: Esen, Idil, et al.
Publicado: (2023)

Baseline Glucocorticoid‐Related Toxicity Scores in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial
por: Patel, Naomi J., et al.
Publicado: (2023)

Hypocomplementemia is associated with worse renal survival in ANCA-positive granulomatosis with polyangiitis and microscopic polyangiitis
por: Deshayes, Samuel, et al.
Publicado: (2018)

Doppler ultrasound and giant cell arteritis
por: Suelves, Ana Marina, et al.
Publicado: (2010)

An Unusual Presentation of Giant Cell Arteritis
por: Prabhavalkar, Siddhesh, et al.
Publicado: (2012)

Biologic Therapies for Giant Cell Arteritis
por: Harrington, Robert, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_isbut4g5n6v15mlk8qd5slu5l8